Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Analytical and characterisation instruments

SubmarketREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Analytical and characterisation instruments

Instruments used to identify, measure, image or characterise molecules, cells, materials and biological processes, including mass spectrometry, chromatography, spectroscopy, microscopy and sequencing platforms.

Market size
$65.9B
$65.9B ($62.5B–$70.0B) · 2026 · Proxy
Growth
+6.0%
$105B by 2034
Attractiveness
80 /100
for B2B sellers
Evidence
Medium confidence
2 sources · Proxy
Level
Submarket
Segmented by
Use case
Buyers
Pharmaceutical and biotechnology companies, contract research and manufacturing organisations, academic research institutions
Buying centre
Research and analytical scientists, laboratory directors, procurement, finance, regulatory affairs
Maturity
Growth
Structure
Moderately concentrated
Buying triggers
  • Laboratory build-outs and instrument replacement budgets
  • New research programmes requiring platform capability
  • Biotech financing and pharma R&D budget releases
  • Demand for automated sample preparation and analysis
Pains
  • Capital cost and total-cost-of-ownership concerns
  • Instrument downtime and service response times
  • Method transfer and reproducibility issues
  • Data integration with laboratory workflows
Scores (1–5)
Pain intensity4
Purchasing power4
Reachability4
Growth4
Growth drivers
  • Demand for mass spectrometry, chromatography, microscopy and sequencing platforms
  • Pharmaceutical and biotechnology R&D expansion
  • Replacement of ageing laboratory equipment
  • Automation and throughput requirements
Headwinds
  • High capital cost and long procurement cycles
  • Biotech funding constraints
  • Service and installation dependencies
  • Regulatory validation requirements
Trends
  • Benchtop instrument consolidation
  • Cloud and remote-service integration
  • Higher-throughput and automated workflows
  • Multi-technique characterisation platforms

Niches 4

Split by customer type.

Niche70/100

Discovery-stage molecular and proteomics characterisation platforms

Analytical and characterisation instruments bought by discovery-stage biotechnology and pharmaceutical companies, and by discovery research groups within contract research organisa

—
Discovery-stage biotechnology and pharmaceutical companies; discovery research units in contract research organisations
not sizedOpen
Niche70/100

Preclinical development and translational research characterisation platforms

Analytical and characterisation instruments bought by pharmaceutical and biotechnology companies, and by contract research organisations serving them, to quantify drug candidates,

—
Preclinical development functions in pharmaceutical and biotechnology companies; bioanalytical and DMPK laboratories in contract research organisations
not sizedOpen
Niche75/100

Regulated manufacturing and quality-control characterisation systems

Analytical and characterisation instruments bought by pharmaceutical and biotechnology companies, contract development and manufacturing organisations, and contract research organi

—
Quality control, analytical development and manufacturing organisations in pharmaceutical and biotechnology companies; contract development and manufacturing organisations
not sizedOpen
Niche80/100

Sequencing and single-cell spatial characterisation platforms

Sequencing, imaging and single-cell analysis platforms bought by pharmaceutical and biotechnology companies, contract research organisations and academic research institutions to c

—
Genomics, translational medicine and cell biology teams in pharmaceutical and biotechnology companies; genomics and single-cell service lines in contract research organisations; genomics and imaging research groups in academic research institutions
not sizedOpen

Companies in this market 8

Named in public sources; linked to the source.

How this was sized

$65.9B ($62.5B–$70.0B) · 2026 · Proxy

Proxy from published life-science instrumentation markets: USD 65.92B in 2026 (Fortune Business Insights) and USD 70.02B in 2026 for life-science and chemical instrumentation (Mordor Intelligence); the midpoint is used. The 2034 forecast of USD 105.33B and 6.0% CAGR are from Fortune Business Insights. Instrumentation is a subset of the broader life-science tools market.

Alongside it in Life-science tools, instruments and laboratory services

// Sell into Analytical and characterisation instruments

AOS finds the biggest accounts in this submarket with a reason to talk now, maps their buying centre and prepares the outreach for your approval.